7.21
-0.18 (-2.44%)
| 前收盘价格 | 7.39 |
| 收盘价格 | 7.51 |
| 成交量 | 52,959 |
| 平均成交量 (3个月) | 232,243 |
| 市值 | 653,634,112 |
| 市盈率 (P/E TTM) | 360.50 |
| 价格/销量 (P/S) | 7.38 |
| 股市价格/股市净资产 (P/B) | 9.67 |
| 52周波幅 | |
| 利润日期 | 11 Aug 2025 |
| 营业毛利率 | 7.20% |
| 营业利益率 (TTM) | 10.31% |
| 稀释每股收益 (EPS TTM) | 0.020 |
| 季度收入增长率 (YOY) | -18.80% |
| 季度盈利增长率 (YOY) | -64.20% |
| 总债务/股东权益 (D/E MRQ) | 1.52% |
| 流动比率 (MRQ) | 3.60 |
| 营业现金流 (OCF TTM) | -6.65 M |
| 杠杆自由现金流 (LFCF TTM) | -8.55 M |
| 资产报酬率 (ROA TTM) | 5.18% |
| 股东权益报酬率 (ROE TTM) | 12.12% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Gyre Therapeutics, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.25 |
|
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 91.25% |
| 机构持股比例 | 2.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Advantage Alpha Capital Partners Lp | 31 Mar 2025 | 13,663 |
该时间范围内无数据。
该时间范围内无数据。
| 3年平均股息收益率 | 6.31% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 现金 |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 现金 |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.93 |
| 2022 | 1.43 | 1 | 17.99 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合